Cellebrite DI Ltd. CLBT
10.79
(0.58)
(5.10%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 45.0×
Follow CLBT
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
59.77 | 56.34 | 47.52 | 60.83 |
P/S ratio |
9.90 | 9.16 | 6.84 | 7.03 | |
P/FCF ratio |
33.31 | 402.64 | 1,262.12 | 0.00 | |
P/Operating CF |
135.62 | 50.18 | 170.80 | 205.54 | |
P/B ratio |
10.08 | 9.00 | 6.65 | 6.72 | |
Price to Tangible BV |
11.03 | 15.38 | 12.91 | 12.19 | |
EV/Sales |
8.74 | 8.24 | 5.98 | 6.17 | |
EV/EBITDA |
57.79 | 51.59 | 38.75 | 41.53 | |
EV/Operating CF |
26.11 | 22.58 | 17.20 | 20.14 | |
EV/FCF |
29.43 | 362.24 | 1,102.67 | (158.29) | |
Quick Ratio |
1.99 | 1.47 | 1.43 | 1.52 | |
Current Ratio |
2.11 | 1.56 | 1.54 | 1.62 | |
Net Debt/EBITDA |
(24.79) | (17.77) | (28.65) | (28.32) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.62 | 0.58 | 0.60 | 0.58 | |
Operating CF/Net income |
1.65 | 4.08 | 1.82 | 2.76 | |
Capex/Depreciation |
(1.50) | (40.02) | (1.72) | (1.34) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
22.32% | 23.18% | 27.96% | 27.42% | |
Selling, General and Administrative Expense of Revenue |
46.50% | 45.38% | 47.46% | 48.06% | |
Intangible Assets out of Total Assets |
0.05 | 0.21 | 0.26 | 0.24 | |
Share Based Compensation of Revenue |
12.15% | 9.31% | 11.21% | 11.63% | |
Graham Net Nets |
0.06 | 0.03 | 0.03 | 0.04 | |
Graham Number |
3.58 | 3.80 | 3.68 | 3.43 | |
Earnings Yield |
1.67% | 1.77% | 2.10% | 1.64% | |
Free Cash Flow Yield |
3.00% | 0.25% | 0.08% | (0.55%) | |
Revenue per Share |
0.52 | 0.53 | 0.52 | 0.53 | |
Operating CF per Share |
0.14 | 0.36 | 0.08 | 0.07 | |
Capex per Share |
(0.01) | (0.63) | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.12 | (0.27) | 0.04 | 0.02 | |
Cash per Share |
2.16 | 1.81 | 1.74 | 1.79 | |
Shareholders Equity per Share |
1.84 | 2.00 | 2.07 | 2.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.84 | 2.00 | 2.07 | 2.17 | |
Free Cash Flow |
29.95 | (64.60) | 9.79 | 5.96 | |
Working Capital |
351.49 | 206.19 | 190.66 | 225.47 | |
Capital Expenditures |
(3.32) | (151.41) | (10.10) | (11.63) | |
Net Current Asset Value |
281.77 | 121.32 | 99.12 | 133.47 | |
EV/EBIT |
64.92 | 58.96 | 46.85 | 56.79 | |
Capex to Sales |
0.03 | 1.18 | 0.08 | 0.09 | |
Net Profit Margin |
16.02% | 16.50% | 8.53% | 4.86% | |
Price to Operating Income |
73.49 | 65.53 | 53.63 | 64.72 | |
| Other line items | |||||
Average Receivables |
98.96 | 93.67 | 76.94 | 101.95 | |
Average Payables |
67.69 | 81.24 | 77.33 | 86.84 | |
Average Inventory |
9.19 | 8.27 | 8.25 | 8.96 | |
Average Assets |
731.78 | 814.71 | 831.09 | 890.87 | |
Average Common Equity |
373.00 | 410.17 | 437.02 | 473.26 |
Columns are period end dates